12:00 AM
Feb 04, 2013
 |  BioCentury  |  Finance

Wale(s) of experience

Arthurian plans 10-12 drug, Dx, medtech investments for Welsh fund
Wale(s) of experience

A group of seasoned life science investors, academics and former executives surfaced last week as board members of Sir Chris Evans' new investment firm Arthurian Life Sciences. The group's first task is managing the recently created Welsh Life Sciences Fund.

The Welsh government committed £50 million ($78.7 million) to the fund last year and recently awarded Arthurian a contract to manage the fund. Arthurian board member Martin Walton told BioCentury the firm is now...

Read the full 357 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >